MétaCan
Menu
Back to cohort
Record W2622107576 · doi:10.1002/hon.2438_75

Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 <scp>DAWN</scp> study

2017· article· en· W2622107576 on OpenAlexaff
Nathan Fowler, Ajay K. Gopal, Stephen J. Schuster, Judith Trotman, J. Hou, Abdulraheem Yacoub, Michael Lill, Peter Martin, Umberto Vitolo, Andrew Spencer, John Radford, Wojciech Jurczak, James Morton, Dzhelil Osmanov, Dolores Caballero, Sanjay Deshpande, Jessica Vermeulen, Rajendra N. Damle, Michael Schäffer, S. Balasubramanian, Bruce D. Cheson, Gilles Salles

Bibliographic record

VenueHematological Oncology · 2017
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsHatch (Canada)
Fundersnot available
KeywordsMedicineFollicular lymphomaInternal medicineLymphomaGastroenterologyRegimenPhases of clinical researchFlow cytometryOncologyImmunologyToxicity

Abstract

fetched live from OpenAlex

Background: Ibrutinib (ibr), a first-in-class, oral, covalent Bruton's tyrosine kinase inhibitor, is approved for and has demonstrated robust activity in various B-cell non-Hodgkin lymphomas. The DAWN study (FLR2002, NCT01779791) investigated the efficacy and safety of single-agent ibr in chemoimmunotherapy (CIT)-refractory follicular lymphoma (FL) patients (pts). Ibr may modulate T-cell activity via inhibition of interleukin-2-inducible T-cell kinase by activating T-helper 1 (Th1) cells (Dubovsky, et al. Blood 2013). We describe the effect of ibr treatment on T-cells and cytokines in pts in the DAWN study. Methods: This was a multicenter, single-arm, phase 2 study of ibr in FL pts with ≥2 prior lines of therapy and progressive disease (PD) ≤ 12 months after CIT regimen. Pts received ibr (560 mg QD) on a 21-day cycle until PD or toxicity. A protocol amendment allowed continued ibr treatment in clinically stable/improving pts with radiological evidence of PD (new lesion/increase ≥50%) to account for “pseudo-PD”. The primary end point was the overall response rate (ORR) (complete response [CR] + partial response). Flow cytometry assessed T-cell subsets in peripheral blood at baseline (C1D1) and at cycle 3 (C3D1) for 57 pts (14 responders, 43 nonresponders); cytokine and chemokine analyses were performed at C1D1 and at cycle 2 (C2D1) for 50 pts (21 responders, 29 nonresponders). Results: The DAWN study results have been presented (Gopal A, et al. ASH 2016); ibr achieved an ORR of 20.9% (CR rate, 10.9%). Flow cytometry analysis revealed CD4 + CD25 + CD127− Tregs were downregulated at C3D1 in responders (CR + PR, mean decrease 17 to 12.9% CD4, p = 0.02) but not in nonresponders (11.5 to 10.4% CD4, p = 0.17). There were no differences between responders and nonresponders in a large panel of inflammation-related cytokines and chemokines at C1D1, confirmed by gene expression profiling in the tumor. After 21 days, Th1 cytokines interferon (IFN)-γ and interleukin (IL)-12 were increased in responders but decreased in nonresponders (p = 0.0025 and p = 0.035, respectively; Figure). The chemokines IFN-γ-induced protein 10 and monocyte-chemotactic protein 3 were decreased in responders but increased in nonresponders (p = 0.022 and 0.016, respectively). Available data in pseudo-PD pts showed a similar trend of decreased Tregs at C3D1 as responders, but the cytokines showed a similar trend as nonresponders. Keywords: follicular lymphoma (FL); ibrutinib; immunomodulators (IMIDs)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.084
Threshold uncertainty score0.505

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.377
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueHematological OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207